Drug – bio-affecting and body treating compositions – Topical body preparation containing solid synthetic organic... – Ophthalmic preparation
Reexamination Certificate
1999-03-10
2001-07-17
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Topical body preparation containing solid synthetic organic...
Ophthalmic preparation
C514S912000, C514S913000
Reexamination Certificate
active
06261545
ABSTRACT:
TECHNICAL FIELD
This invention relates to an ophthalmic composition and an optic nerve functional disorder-treating agent which contain a neurotrophic factor, a contact lens into which this is formulated, and a method for treating an optic nerve functional disorder. More specifically, it relates to an ophthalmic composition, a treatment agent and a treatment method particularly effective for treating glaucoma.
BACKGROUND ART
Recently, it is said that one person per 30 to 40 persons of forty years and over suffers from glaucoma. Patients with this glaucoma tend to be increased every year, and glaucoma becomes a serious problem in the society where the aged is being increased. Therefore, establishment of a method for treating glaucoma which has not been established in the prior art has an important meaning, and also, a treatment agent effective for this glaucoma has been demanded.
Glaucoma is an optic nerve functional disorder caused by pressing an optic nerve by an optic disk which is an entrance and exit of an eyeball due to raising of intraocular pressure to cause a functional disorder. It is also considered that raising of intraocular pressure becomes a trigger of apoptosis of an optic nerve to cause an optic nerve functional disorder.
In conventional treatment of glaucoma, only intraocular pressure has been lowered by the dropping of a &bgr;-blocker in the eyes or internal application of an the intraocular pressurelowering agent. However, even when the intraocular pressure is lowered, the lowering of eyesight and the stricture of a visual field continue to proceed and cannot be prevented even by administering vitamin B
12
and a blood stream-improving agent in some cases.
Therefore, the lowering of intraocular pressure is insufficient, and a medicine which takes charge of functional maintenance, improvement, growth and regeneration of an optic nerve itself is required for treatment of an optic nerve functional disorder. Also, a medicine for preventing apoptosis of an optic nerve is required.
SUMMARY OF THE INVENTION
In order to solve the above problem, the present inventor has found an ophthalmic composition and an optic nerve functional disorder-treating agent which contain a neurotrophic factor, a contact lens into which this is formulated, and a method for treating an optic nerve functional disorder using them, to accomplish the present invention.
An object of the present invention is to provide an ophthalmic composition which is useful for treating an optic nerve functional disorder, particularly glaucoma by preventing apoptosis and directly acting on an optic nerve. Another object of the present invention is to provide an ophthalmic composition which is useful for treating an optic nerve functional disorder, particularly glaucoma with less side effects.
Also, an object of the present invention is to provide an ophthalmic composition which can treat an optic nerve functional disorder by a simple and easy administration method without casting a heavy burden upon a patient and a doctor. Further, an object thereof is to provide a contact lens into which this is formulated. Additionally, an object thereof is to provide a method for treating an optic nerve functional disorder by administering these ophthalmic compositions.
The present invention relates to an ophthalmic composition which comprises a neurotrophic factor.
Also, the present invention relates to an optic nerve functional disorder-treating agent which comprises a neurotrophic factor.
Further, the present invention relates to a method for treating an optic nerve functional disorder, which comprises administering an effective amount of a neurotrophic factor.
REFERENCES:
patent: 5270051 (1993-12-01), Harris
patent: 5349056 (1994-09-01), Panayotatos
patent: 5641749 (1997-06-01), Yan et al.
patent: 5641750 (1997-06-01), Louis
patent: 5667968 (1997-09-01), LaVail et al.
patent: 219207 (1987-04-01), None
patent: 443809 (1991-08-01), None
patent: 57-203440 (1982-12-01), None
patent: WO93/25684 (1993-12-01), None
patent: WO95/26363 (1995-10-01), None
patent: WO96/06859 (1996-07-01), None
patent: WO97/34586 (1997-09-01), None
Olivia Bermingham-McDonogh, Kathryn L. McCabe and Thomas A. Reh, “Effects of GGF
euregulins on Neuronal Survival and Neurite Outgrowth Correlate with erbB2
eu Expression in Developing Rat Retina”,Development, 122, 1427-1438, (1996).
Ramesh C. Tripathi, Navaneet S.C. Borisuth and Brenda J. Tripathi, “Growth Factors in the Aqueous Humor and Their Therapeutic Implications in Glaucoma and Anterior Segment Disorders of the Human Eye”,Drug Development Research, 22:1-23 (1991).
Advanced Medicine Research Institute
Azpuru Carlos A.
Frishauf, Holtz Goodman, Langer & Chick, P.C.
LandOfFree
Ophthalmic compositions of neurotrophic factors, remedies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic compositions of neurotrophic factors, remedies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions of neurotrophic factors, remedies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2546462